1. Introduction {#s0005}
===============

Crimean-Congo hemorrhagic virus (CCHFV) is an enveloped, segmented negative-stranded RNA virus belonging to the *Nairovirus* genus of the *Bunyaviridae* family. The virus is endemic in western areas of the former Soviet Union and in southeastern and southwestern Europe; eastern and central Asia ([@b0015]). *Hyalomma* spp. ticks are considered to be the most important vector for human transmission in the epidemiology of CCHF. Human to human transmission was documented after contact with blood and other body fluids. Human infection with CCHFV often results in severe hemorrhagic disease characterized by extensive ecchymosis, visceral bleeding, hepatic dysfunction ([@b0075]) with high case mortality rates. The average mortality rate is often cited at 30% ([@b0015]).

In a CCHFV infection context the current medical management is largely based on the treatment of symptoms. Currently, the only drug used to treat CCHFV infection is the ribavirin. Ribavirin antiviral therapy have to be initiated as soon as possible to be effective ([@b0225]). However, there is still a debate on the ribavirin therapeutic beneficial treatment ([@b0215]). Other treatments such as type I interferon ([@b0235]); corticosteroid therapy ([@b0070]), or the efficient polyclonal anti-CCHFV human immunoglobulin treatment, ([@b0240]), were tested without removing the need of new antiviral molecules.

In the present study, we aimed at characterizing the *in vitro* anti CCHFV efficacy of chloroquine and chlorpromazine.

Chloroquine was used to prevent and treat malaria ([@b0190]). It was also shown that chloroquine is a broadspectrum molecule displaying an *in vitro* antiviral activity against a range of RNA viruses ([@b0190]). The mechanism of action of chloroquine is multiple, depending on the pathogen, it likely acts via the endosome, lysosome and golgi vesicle pH increase ([@b0195]). Chlorpromazine a well known anti-psychotic drug showed antiviral activity against adenovirus ([@b0065]), Ebola virus ([@b0030]) and coronavirus ([@b0055]). The mechanism of action of chlorpromazine is known to interfere with the formation of clathrin coated pits inhibiting clathrin-mediated endocytosis ([@b0250]).

In this study, chloroquine and chlorpromazine were found to inhibit CCHFV replication *in vitro*, even if added up to 6 h post infection. Moreover when these two molecules were in combination to ribavirin, a synergistic effect was observed in Vero E6 cells. Further studies on the anti-CCHFV efficacy of these two FDA-approved drugs should be investigated in KO mice models.

2. Materials and methods {#s0010}
========================

2.1. Cells and viruses {#s0015}
----------------------

Vero E6 (African green monkey kidney, ATCC CRL-1586) and Huh7 (hepatocarcinoma cell line; CelluloNet, Cat N°120, Lyon, France) cells were grown at 37 °C in DMEM (Gibco®, Life technologies™) supplemented with 10% inactivated fetal calf serum (FCSi, Gibco®, Life technologies™), 1% NEAA 100× (Gibco®, Life technologies™) and 1% penicillin--streptomycin (PS) (10,000 U penicillin/ml; 10,000 U streptomycin/ml; Gibco®, Life technologies™).

All work involving infectious viruses was carried out in a biosafety level 4 (BSL-4) facility.

The stocks of 86--07 (IbAr10200, Nigeria) and 87--07 (ArD39554, Mauritania) CCHFV strains were prepared in Vero E6 cells and titrated by plaque formation on Vero E6 cells as previously described ([@b0165]).

2.2. Toxicology study {#s0020}
---------------------

Chloroquine (C6628; Sigma), chlorpromazine (C8138; Sigma) and ribavirin (R9644; Sigma) were dissolved in water and were stored in 100 mM stock solutions at −20 °C until use.

Confluent cell monolayers of Vero E6 and Huh7 cells were incubated in DMEM supplemented with 2.5% FCSi with different concentrations of the molecules, ranging from 0 to 1000 μM of chloroquine and chlorpromazine. Cytotoxic effects were monitored at 4, 24, 48 and 72 h of treatment. Cell viability was measured using the Cell proliferation kit (MTT; Roche) according to the manufacturer's instructions. The 50% cytotoxic concentrations (CC~50~) of chloroquine and chlorpromazine were then determined. Three independent experimentations were performed in duplicate. The selectivity index (SI) which correspond to the relative effectiveness of the drugs in inhibiting viral replication compared to inducing cell death was then determined.

2.3. Inhibition of virus infection by inhibitor treatment {#s0025}
---------------------------------------------------------

### 2.3.1. Plaque reduction assay {#s0030}

For CCHFV studies, Vero E6 or Huh7 cells were seeded in 12 well plates (BD Falcon) at a density of 4 × 10^5^  cells per well. After an overnight incubation at 37 °C, infections with CCHFV (strains 86--07; 87--07) were carried out at a MOI of 0.025. Final molecule concentrations tested ranged from 0 to 250 μM (CQ) and from 0 to 50 μM (CPZ). The 250 μl of CCHFV inoculum was removed after a 1 h incubation at 37 °C then the cells were further incubated at 37 °C after the addition of 2 ml of 3.2% carboxymethylcellulose (CMC, Sigma--Aldrich) in DMEM/2.5% FCSi solution with molecules. At day 3, viral titers were determined as described by [@b0165], except for the revelation step in which True Blue (KPL) reagent was used instead of DAB.

To test the antiviral effect of chloroquine and chlorpromazine, three conditions were assayed pre-treatment (1 h before the infection step), concurrent treatment (during the virus infection step) and permanent treatment (before and during the virus infection step). Three independent experimentations were performed in duplicate.

The 50% inhibitory concentration (IC~50~) and the CC~50~ were calculated with GraphPad Prism 6 software using the non-linear regression model.

### 2.3.2. Effect of addition time {#s0035}

The antiviral effect of chloroquine and chlorpromazine on CCHFV was performed in 12 well plates. After an overnight incubation at 37 °C, Vero E6 cells (4 × 10^5^  cells seeded per well) were infected using the 86--07 CCHFV strain at a MOI of 0.005. Final molecule concentrations were tested at 50 μM for chloroquine and 10 μM for chlorpromazine. The molecules were added after the 1 h viral adsorption step at 37 °C (t0) and then after 1, 3, 6 or 24 h post-infection (p.i.). Supernatants were harvested at 0, 1, 3, 6, 24 and 48 h p.i., then virus titers were determined by plaque reduction assay as described in 2.3.1 [Section](#s0030){ref-type="sec"}. Four independent experimentations were performed in triplicate.

### 2.3.3. Analysis of the anti-CCHFV effect of molecule combinations {#s0040}

To test if chloroquine or chlorpromazine can be combined with ribavirin, their potential synergistic effect was determined by the isobologram and combination-index methods, derived from the median-effect principle of [@b0045] using the CompuSyn software. Data obtained from the virus growth inhibitory experiments were used to perform these analysis. Vero E6 cells were seeded in 12 well plates (BD Falcon) at a density of 4 × 10^5^  cells per well. After an overnight incubation at 37 °C, cells were infected using CCHFV (strains 86--07) at a MOI of 0.025. Molecules combinations were based on the comparison of their IC~50~. The molecule combinations were performed at a constant ratio. A 5:8 chloroquine/ribavirin and a 2:5 chlorpromazine/ribavirin combination ratio were applied with molecules concentrations ranging from 10 to 160 μM (CQ), 6.25--100 μM (ribavirin), and 2.5--40 μM (CPZ). The combinations were added concomitantly to the CCHFV infection step and maintained during all the experience. The viral inoculum was removed after 1 h at 37 °C and the cells were further incubated at 37 °C after the addition of 2 ml of 3.2% carboxymethylcellulose (CMC, Sigma Aldrich) in DMEM/2.5% FCSi solution. At 72 h p.i., viral titers were determined as described by [@b0165], except for the revelation step in which True Blue (KPL) reagent was used instead of DAB.

The combinations were tested and compared to three theoretical fractional virus inhibition values (Fa), i.e., 0.5 corresponding to a 50% theoretical inhibition, 0.75 (a 75% theoretical inhibition) and 0.9 (a 90% theoretical inhibition). Three independent experimentations were performed in duplicate.

The isobologram method is a graphical representation of the pharmacologic interaction among the molecules. When the combination given values were shown to be under the theoretical additive effects line (represented in the graph by the three segments linking the IC~50~, the IC~75~ and the IC~90~ of the two molecules) they were considered synergic molecules whereas values above the threshold were considered antagonistic molecules.

3. Results {#s0045}
==========

3.1. Dose dependent inhibition of 86--07 and 87--07 CCHFV strains {#s0050}
-----------------------------------------------------------------

Chloroquine was found to reduce the amount of 86--07 CCHFV infectious particles released from infected cells in a dose dependent manner displaying an IC~50~ of 39.4 μM ([Fig. 1](#f0005){ref-type="fig"} a and [Table 1](#t0005){ref-type="table"} ). Interestingly, chloroquine efficacy was confirmed using another CCHFV strain, 87--07, showing an IC~50~ of 28.1 μM. An antiviral effect was also observed with chlorpromazine using the two CCHFV strains. A higher inhibiting efficacy was observed using chlorpromazine when compared to chloroquine; the IC~50~ ranged from 10.6 to 15.8 μM ([Fig. 1](#f0005){ref-type="fig"}b). However, due to a weaker cytotoxic effect, the chloroquine relative efficacy (SI) appeared higher than the chlorpromazine one ([Table 1](#t0005){ref-type="table"}).Fig. 1*In vitro* determination of IC~50~ by a plaque reduction assay. The 50% inhibitory concentration (IC~50~) for chloroquine and chlorpromazine was determined in duplicate in 12 well plates on monolayers of Vero E6 (a and b), or Huh7 (c and d) cells. Two CCHFV strains were used, 86--07 strain (circle), 87--07 strain (triangle). Plaques were enumerated after immunostaining. The dose response curves were sigmoid, and log (inhibitor) vs response curve was performed using GraphPad Prism 6, GraphPad software, [www.graphpad.com](http://www.graphpad.com){#ir005}.Table 1IC~50~ and CC~50~ using Vero E6 and Huh7 cells and CCHFV strains 86--07 and 87--07.Vero E6Huh7CCHFV strain86--0787--07MoleculeIC~50~ (μM)*p* ValueCC~50~ (μM)SIIC~50~ (μM)*p* ValueCC~50~ (μM)SIIC~50~ (μM)*p* ValueCC~50~ (μM)SIChloroquine39.4 (±0.031)100026.928.1 (±0.042)ns[a](#tblfn1){ref-type="table-fn"}100035.643.4ns[b](#tblfn2){ref-type="table-fn"}92621.3Chlorpromazine10.6 (±0.031)302.815.8 (±0.051)ns[a](#tblfn1){ref-type="table-fn"}301.94.3^⁎⁎,^[b](#tblfn2){ref-type="table-fn"}307.1[^2][^3][^4][^5][^6][^7]

The liver being a key target organ for CCHFV, the chloroquine and chlorpromazine efficacies were also evaluated using Huh7 hepatocytes. Infecting these cells with 86--07 CCHFV strain, the chloroquine IC~50~ was 43.4 μM which is close to the one showed in Vero E6 ([Fig. 1](#f0005){ref-type="fig"}c and [Table 1](#t0005){ref-type="table"}). Interestingly, the chlorpromazine efficacy was stronger in Huh7 than in Vero E6 cells ([Fig. 1](#f0005){ref-type="fig"}d and [Table 1](#t0005){ref-type="table"}).

3.2. Effect of the pre, concurrent and post-infection molecule addition {#s0055}
-----------------------------------------------------------------------

Permanent treatment with either chloroquine or chlorpromazine highlighted the efficacy of the two inhibitors. We investigated antiviral activity of chloroquine and chlorpromazine when added before (pre-treatment) and during (concurrent) the CCHFV infection.

The chloroquine efficacy was similar in the concurrent and permanent conditions ([Table 2](#t0010){ref-type="table"} ). The pre-treatment was shown not to improve chloroquine efficacy. Similar observations were obtained using chlorpromazine ([Table 2](#t0010){ref-type="table"}).Table 2Effect of molecule addition time on potency and efficacy of chloroquine and chlorpromazine.ConditionsEfficacyChloroquineChlorpromazineIC~50~ (μM)SD*p* ValueIC~50~ (μM)SD*p* ValuePretreatment88.90.11[⁎⁎](#tblfn7){ref-type="table-fn"}^,^[b](#tblfn5){ref-type="table-fn"}16.30.08[⁎](#tblfn6){ref-type="table-fn"}^,^[b](#tblfn5){ref-type="table-fn"}Concurrent41.20.02ns[a](#tblfn4){ref-type="table-fn"}6.70.02ns[a](#tblfn4){ref-type="table-fn"}Permanent37.20.0318.50.04[^8][^9][^10][^11][^12][^13]

When, chloroquine and chlorpromazine were added at several time post infection, i.e., 1, 3, 6 and 24 h p.i. at a concentration close to the IC~50,~ obtained in the permanent treatment conditions, at 24 h p.i. the CCHFV titers were reduced by ∼1 log~10~ when chloroquine was added up to 6 h p.i. ([Fig. 2](#f0010){ref-type="fig"} a) and reduced by ∼1.5 log~10~ when chlorpromazine was added up to 6 h p.i. ([Fig. 2](#f0010){ref-type="fig"}b.). At 48 h p.i. CCHFV titers were still reduced when chloroquine was added up to 6 h p.i. (∼0.5 log~10~ reduction) and chlorpromazine was added up to 24 h p.i. (∼1 log~10~ reduction).Fig. 2Effect of period of addition of molecules on virus yield infection. Virus yield inhibitions were performed on Vero E6 cells. Cells were infected with CCHFV 86--07, MOI 0.005. Chloroquine (a) or chlorpromazine (b) were only added during the post infection step. Five conditions were investigated; molecules were added just after the infection step (t0), 1, 3, 6, 24 h.p.i. Supernatants and cells were harvested 24 and 48 h.p.i., and the viral yield in supernatant was determined by plaque titration. When *p*-value \<0.001 "\*" was added.

3.3. Synergistic inhibition of CCHFV using ribavirin in combination to chloroquine or chlorpromazine {#s0060}
----------------------------------------------------------------------------------------------------

Because ribavirin, chloroquine and chlorpromazine are described to have distinct modes of action, we wondered whether the combination of these molecules might improve their antiviral activity. We performed assays in which Vero E6 cells were infected with CCHFV then subsequently treated with ribavirin in combination to either chloroquine or chlorpromazine at constant concentration ratios ([@b0045]).

As shown in [Fig. 3](#f0015){ref-type="fig"} a, when Vero E6 cells were treated with the CQ/ribavirin combination, the observed CCHFV inhibition values were all below the additive theoretical lines. Therefore, a significant synergistic antiviral activity was observed for the chloroquine molecule in combination with ribavirin. Similar results were obtained using the ribavirin/chlorpromazine combination ([Fig. 3](#f0015){ref-type="fig"}b).Fig. 3Isobolograms of *in vitro* drug combinations. Vero E6 cells were seeded in 12-well plates, allowed to attach for 24 h and infected with a standard dose of CCHFV with graded concentrations of ribavirin, chloroquine, chlorpromazine in combination for 72 h. After the determination of IC~50~ value for each drug, combinations were done using a constant drug ratio (IC~50~ ratio). Combination studies were done using ribavirin/CQ ratio of 5:8; ribavirin/CPZ of 5:2 over the range of drug concentrations tested. Normalized Fa0.5 (50% inhibition), Fa0.75 (75% inhibition) and Fa0.90 (90% inhibition)-isobolograms of constant dose ratios showing interaction between chloroquine and ribavirin; chlorpromazine and ribavirin. The oblique lines between *X* and *Y* axis indicates the theoretical doses that produce an additive effect (Fa0.50: straight line; Fa0.75: dash line; Fa0.90: dot line). Interaction between drugs inducing 50, 75 and 90% of inhibition are represented by square (Fa0.5), open triangle (Fa0.75) and open circle (Fa0.90). A point below the theoretical line represents a synergistic interaction, A point above the theoretical line represents antagonistic interaction.

4. Discussion {#s0065}
=============

The worldwide circulation of CCHFV mainly in countries in the south of the 50th parallel north ([@b0085]) together with the CCHFV human case number increase in Turkey ([@b0115]).and the lack of efficient specific treatment emphasized the need of new antiviral molecules development.

Despite a high mortality rate, the current medical management is largely supportive. Until now ribavirin is the only antiviral treatment implemented in CCHF, which is still debated ([@b0215]). A strategy to reduce the time of drug development could be the recycling use of existing drugs in other conditions. In this work, we took advantage of the CCHFV entry pathway discovery ([@b0210], [@b0105]). We investigated the anti CCHFV activity of approved molecules known to inhibit endocytic pathways. From initial *in vitro* antiviral testing (data not shown), we have identified the antiviral effect of two molecules known to inhibit the clathrin/pH dependent endocytic pathway.

The results presented in this *in vitro* study showed that chloroquine and chlorpromazine are effective antiviral molecules for CCHFV. The IC~50~ of chloroquine and chlorpromazine inhibition of CCHFV were 39.4 and 10.6 μM respectively.

Chloroquine was found to be the most selective CCHFV inhibitor with a selective index of more than 20. Chloroquine is a weak base that is known to affect acid vesicles leading to dysfunction of several enzymes including acid hydrolases inhibiting post-translational modification ([@b0180]), therefore potentially affecting pH-dependent entry of viruses ([@b0110]).

Chloroquine has been in use for many years for the treatment of malaria and for the long term prophylaxis of inflammatory diseases. Ocular toxicity ([@b0130]), cardiotoxicity ([@b0230]) and oral mucosa hyperpigmentation ([@b0050]) are known complication of long term use of chloroquine. Reversible side effect can be observed for mucosal pigmentation after months of discontinuation of chloroquine treatment ([@b0005]). Cardiomyopathy side effect can be lessened after cessation of chloroquine treatment and prescription of a combined therapy of candesartan and carvedilol treatment ([@b0150]). Contrary to hyperpigmentation and cardiomyopathy, retinopathy is an irreversible side effect of long term chloroquine treatment and can appear even after usage of chloroquine has stopped ([@b0130]). Nevertheless, daily dose of the chloroquine seems to be relevant for the development of ocular side effect, the risk of retinopathy is lowered if this dose not exceed 4 mg/kg/day ([@b0145]) or is minimal when the daily dose not exceed 250 mg ([@b0005]).

Previously, chloroquine was proposed to be used against several viral infections ([@b0190]). The antiviral efficacy of this molecule was shown on different cell culture with IC~50~ related to each pathogens. Chloroquine was shown to inhibit Chikungunya virus (IC~50~ 10 μM) ([@b0140]), Dengue virus ([@b0090]), coronavirus (IC~50~ 8.8 μM) ([@b0135]), MERS-CoV (IC~50~ 3.0 μM) ([@b0055]), influenza virus (IC~50~ 3.6 μM) ([@b0160]), or Henipavirus (IC~50~ 2 μM) ([@b0175]). Chloroquine was also used to inhibit HIV 1 in lineages of monocytes and lymphocytes ([@b0220]) which are known to be HIV 1 target cells. In adults a 10 mg/kg CQ oral dose is followed by a 263 ng/ml plasma peak concentration ([@b0245]), which is close to the chloroquine IC~50~. Moreover chloroquine is known to accumulate in CCHFV target organs, such liver and spleen ([@b0120]). In this study, a similar chloroquine SI was assessed in two permissive cells (Vero E6) and human target cells (Huh7). The chloroquine post infection addition was inefficient for influenza viruses ([@b0060]), while was efficient 2 h post CHIKV infection ([@b0140]). In the same way, CCHFV titer was still reduced when chloroquine was added up to 6 h p.i., suggesting that chloroquine blocks a post entry step in CCHFV replication cycle. In this case, rapid elevation of endosomal pH and abrogation of virus endosome fusion might be the primary mechanism by which virus infectivity is inhibited by chloroquine ([@b0170]). The abolishment of the released of sialyltransferase and the Trans-Golgi Network acidification could account for another inhibitory mechanism ([@b0025]). Plasma chloroquine concentration might be influenced by molecule dosage, but a 10 mg/kg first dose is rapidly detectable with a plasma peak concentration until 263 ng/ml ([@b0245]), with a chloroquine accumulation in CCHFV organ targets, such liver or spleen.

The second molecule tested, chlorpromazine, an approved psychotic drug, was described by others to inhibit the clathrin dependent pathway by reducing the number of coated pits-associated receptors at the cell surface ([@b0250]). Chlorpromazine can be associated with pigmentation of the oral mucosa ([@b0205]). But hepatotoxicity in humans characterized by elevated serum alkaline phosphatases or biliary cirrhosis is the main chlorpromazine side effect ([@b0100]). Hyperglycaemia and hypothermia are also side effect related with chlorpromazine treatment ([@b0040]).

Records of the chlorpromazine used as an antiviral molecule were associated to adenovirus ([@b0065]), Ebola virus ([@b0030]) and more recently, coronavirus treatment ([@b0055]). Depending on chlorpromazine posology, its plasma concentration can reach up to 300 ng/ml in treated patients ([@b0185]).

In this study, the chlorpromazine inhibitory effect was observed in all treatment conditions. Interestingly, chlorpromazine exhibited a marked inhibitory effect on Huh7 cell line, whose caveolae-1 pathway is missing, strongly suggesting the involvement of clathrin mediated endocytosis ([@b0035]). The CCHFV titer was still markedly reduced when chlorpromazine was added up to 24 h p.i., suggesting another post entry inhibitory effect, likely at the assembly and budding already identified for Sindbis and vesicular stomatitis virus ([@b0200]). However the low chlorpromazine selectivity index diminished its potential use in clinic particularly if this drug is used alone.

Ribavirin and chloroquine or chlorpromazine combination assays demonstrated synergistics effects in all tested conditions. It was expected because ribavirin, chloroquine and chlorpromazine had different antiviral mechanisms. Thus, these experiments suggest that these combinatorial treatment could represent a strategy to control CCHFV infection.

Such promising *in vitro* results should be confirmed by a drug efficacy evaluation in animal models. Since 2010, two mice models IFNAR^−/−^ and STAT1^−/−^ were used to assess a ribavirin effect against CCHFV infection ([@b0020], [@b0010]). The observed effects were 60% survivals in STAT1^−/−^ mice and 14% in IFNAR^−/−^ mice ([@b0155]). However, [@b0155] demonstrated that ribavirin was not able to prevent the lethal pathophysiological cascade ([@b0155]). It would be relevant to investigate in the near future these molecules compared to others in protective assays alone or in combination to ribavirin using KO mouse models.
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[^2]: IC~50~: Inhibitory concentration (μM).

[^3]: Cell viability was assayed at 1 d p.i.

[^4]: SI: Selectivity index, CC~50~/IC~50~.

[^5]: *p* Value: ns: non significative, ^⁎^: *p* \< 0.05, ^⁎⁎^: *p* \< 0.005.

[^6]: 86.07 compared to 87--07.

[^7]: Vero E6 compared to Huh7.

[^8]: IC~50~: Inhibitory concentration (μM).

[^9]: ns: Non significative.

[^10]: Permanent compared to concurrent.

[^11]: Permanent compared to pre-treatment.

[^12]: *p* \< 0.05.

[^13]: *p* \< 0.005.
